Floatz logo

Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Sibutramine
Obesity Disorder
FalquetomedP4BBB (74)
Simvastatin
Obesity Disorder
Eli Lilly and CompanyP4BBB (74)
Sitagliptin
Obesity Disorder
Brigham and Women's HospitalP4BBB (74)
Tadalafil
Obesity Disorder
Philip KernP4BBB (74)
Talniflumate
Breast Cancer
Shandong UniversityP4BBB (74)
Tamsulosin
Prostate Cancer
Turku University HospitalP4BBB (74)
Tapentadol
Chronic Pain Syndrome
University of ThessalyP4BBB (74)
Tapentadol
Neuralgia
Aretaieion University HospitalP4BBB (74)
Temsirolimus
Non-Hodgkin Lymphoma
Canadian Cancer Trials GroupP4BBB (74)
Testosterone Cipionate
Prostate Cancer
University of MiamiP4BBB (74)
Testosterone Undecylate
Obesity Disorder
Royal College of Surgeons, IrelandP4BBB (74)
Testosterone Undecylate
Prostate Cancer
Roswell Park Cancer InstituteP4BBB (74)
Thiotepa
Plasma Cell Myeloma
First Affiliated Hospital Xi'an Jiaotong UniversityP4BBB (74)
Toremifene
Breast Cancer
Tianjin Medical University Cancer Institute and HospitalP4BBB (74)
Toripalimab
Breast Cancer
Zhejiang Cancer HospitalP4BBB (74)
Trabectedin
Ovarian Cancer
Grupo Español de Investigación en Cáncer de OvarioP4BBB (74)
(±)-Tramadol
Breast Cancer
Aga Khan UniversityP4BBB (74)
Trastuzumab
Breast Cancer
SWOG Cancer Research NetworkP4BBB (74)
Trastuzumab Deruxtecan
Breast Cancer
SWOG Cancer Research NetworkP4BBB (74)
Trazodone
Major Depressive Disorder
Centre Hospitalier St AnneP4BBB (74)
Trazodone
Sleep Disorder
Johns Hopkins UniversityP4BBB (74)
Trimethoprim
Prostate Cancer
University of California, San DiegoP4BBB (74)
Valsartan
Obesity Disorder
ARKAY TherapeuticsP4BBB (74)
Varinon
Breast Cancer
Alexandria UniversityP4BBB (74)
Venetoclax
Acute Myeloid Leukemia
European Organisation for Research and Treatment of Cancer - EORTCP4BBB (74)
Showing 1801 to 1825 of 42,289 assets
PreviousPage 73 of 1692Next